MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock
$2,700K
Net cash provided by
financing activities
$2,700K
Net (decrease)
increase in cash and cash...
-$1,134K
Canceled cashflow
$2,700K
Share-based compensation
expense
$2,010K
Accrued and other
current liabilities
$311K
Long-term prepaid
contracts
-$257K
Deferred revenue
$252K
Accounts receivable
-$215K
Prepaid expenses and
other current assets
-$149K
Amortization of operating
lease right-of-use...
$98K
Prepaid research and
development
-$72K
Inventory
-$64K
Depreciation
$5K
Accounts payable
$2K
Consumer Health Products
$704K
Net cash used in
operating activities
-$3,828K
Canceled cashflow
$3,435K
Effect of exchange rate
changes on cash
-$6K
Product revenue
$704K
Other segment items
-$46K
Net loss
-$6,869K
Canceled cashflow
$750K
Insurance premium
financing payable
-$299K
Operating lease liability
-$95K
Total operating
expenses
$7,619K
General and
administrative
$4,253K
Research and development
$2,653K
Cost of sales
$646K
Sales and marketing
$67K
Regenerative Biotech
$2,653K
Consumer Health Products
$646K
Back
Back
Cash Flow
source: myfinsight.com
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)